Pharmacologically active novel dauer pheromone compound for controlling aging and stress and method for isolating and characterizing the same

   
   

The present invention discloses a method for effectively isolating and purifying a physiological active dauer pheromone compound having the following structural formula I related to aging and stress of C. elegans, and determination of the structure of such material. First, ethanol extract is prepared by completely concentrating a liquid medium with ethanol after culturing C. elegans on a S. basal liquid medium, and then this ethanol fraction is further extracted with ethyl acetate. Then, impurities are removed from ethyl acetate extract by a silica-gel adsorption chromatography and a pheromone extract is isolated and purified by amine column chromatographic procedures using various solvents as eluent. Finally, a pheromone compound having structural formula I is completely isolated and characterized by size-exclusion HPLC.

A invenção atual divulga um método para eficazmente isolar e purifying um composto ativo physiological do pheromone do dauer que tem a seguinte fórmula estrutural I relacionado ao envelhecimento e ao stress de elegans do C., e a determinação da estrutura de tal material. Primeiramente, o extrato do ethanol é preparado completamente concentrando um meio líquido com o ethanol após ter cultivado elegans do C. em um meio líquido basal do S., e esta fração do ethanol é extraída então mais mais com acetato ethyl. Então, as impurezas são removidas do extrato do acetato ethyl por um chromatography do adsorption do silicone-silica-gel e um extrato do pheromone é isolado e purified por procedimentos chromatographic da coluna do amine usando vários solventes como o eluent. Finalmente, um composto do pheromone que tem a fórmula estrutural I completamente é isolado e caracterizado por tamanho-exclusão HPLC.

 
Web www.patentalert.com

< PPAR compounds

< Modulators of peroxisome proliferator activated receptors (ppar)

> Novel pharmaceuticals

> Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemia

~ 00171